LifeSciVC

APRIL 2, 2024

We are turning a corner, and optimistically that means more private companies will be able to secure the resources they need to advance groundbreaking research through critical value inflection points. We experienced strong enthusiasm for small molecule research in the investor community. What resonated?

Science 67

Science Small Molecule International Clinical Development 67

The Pharma Data

DECEMBER 12, 2020

AstraZeneca has developed a broad range of technologies, initially focused on small molecules and biologics and with a growing focus in precision medicine, genomics, oligonucleotides and epigenetics. The FcRn extends the half-life and hence the availability of pathogenic immunoglobulin G (IgG) antibodies.

Regulations 75

Regulations International Disease Small Molecule 75

The Pharma Data

SEPTEMBER 15, 2020

27 key programs highlighted, including assets that could potentially contribute revenue by 2025 and others in the 2026-2028 time frame. Pfizer shared significant research advances across its various therapeutic areas including candidates with blockbuster potential expected to launch by 2025. mg/dL reduction for placebo.

Vaccine 52

Vaccine Therapies Trials Clinical Trials 52